Share Price and Basic Stock Data
Last Updated: January 9, 2026, 4:27 am
| PEG Ratio | 5.02 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Aarti Pharmalabs Ltd operates in the pharmaceuticals sector, with its stock currently priced at ₹747 and a market capitalization of ₹6,774 Cr. The company reported sales of ₹1,945 Cr for the fiscal year ending March 2023, a significant increase from ₹1,200 Cr in March 2022. However, sales showed a decline in the subsequent fiscal year, with ₹1,853 Cr reported for March 2024. The trailing twelve months (TTM) sales stood at ₹1,906 Cr, indicating a slight contraction in revenue generation. Quarterly sales data reveals a downward trend from ₹531 Cr in September 2022 to ₹440 Cr in September 2023, suggesting challenges in maintaining consistent revenue growth amidst fluctuating demand. The operating profit margin (OPM) was reported at 18% for the fiscal year ending March 2025, reflecting the company’s ability to manage costs effectively despite the declining sales trajectory. Overall, while Aarti Pharmalabs has demonstrated growth in past years, recent trends indicate potential challenges in sustaining revenue momentum.
Profitability and Efficiency Metrics
The profitability of Aarti Pharmalabs is highlighted by a net profit of ₹240 Cr for the fiscal year ending March 2025, an increase from ₹217 Cr in March 2024. The net profit margin improved to 12.87%, up from 11.70% in the previous fiscal year, showcasing enhanced cost management and operational efficiency. The company reported an interest coverage ratio (ICR) of 17.64x, indicating a strong ability to meet interest obligations, which is significantly higher than typical sector standards. The return on equity (ROE) stood at 14.5%, while return on capital employed (ROCE) was reported at 17.4%, both metrics indicating effective utilization of shareholder funds and capital. However, the cash conversion cycle (CCC) of 200 days suggests that Aarti Pharmalabs may face challenges in managing working capital efficiently, which could impact liquidity. Despite these challenges, the company’s operating profit margin (OPM) has shown resilience, standing at 18% for the fiscal year ending March 2025.
Balance Sheet Strength and Financial Ratios
Aarti Pharmalabs’ balance sheet reflects a total equity of ₹2,001 Cr as of September 2025, with borrowings reported at ₹659 Cr, indicating a manageable debt level with a total debt-to-equity ratio of 0.19. The company’s reserves have grown from ₹1,386 Cr in March 2022 to ₹2,001 Cr in September 2025, underscoring a robust financial foundation. The current ratio stood at 2.01, suggesting strong liquidity, while the quick ratio of 1.12 indicates adequate short-term financial health. However, the inventory turnover ratio of 3.44x suggests that the company may need to improve its inventory management practices. Furthermore, the price-to-book value ratio (P/BV) of 3.41x indicates that the stock is trading at a premium compared to its book value, which could reflect investor expectations for future growth. Overall, Aarti Pharmalabs demonstrates a solid balance sheet with a healthy mix of equity and manageable debt levels.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Aarti Pharmalabs indicates a diverse ownership structure, with promoters holding 42.88% of the company as of September 2025. This represents a decline from 46.30% in September 2023, suggesting a gradual dilution of promoter stake, which may raise concerns among investors regarding long-term commitment. Foreign institutional investors (FIIs) accounted for 8.02%, while domestic institutional investors (DIIs) held 6.95%, indicating moderate institutional interest. Public shareholders constitute 42.12% of the total shareholding, reflecting a balanced distribution of ownership. The number of shareholders stood at 1,90,655, highlighting a significant retail investor base. The gradual decline in promoter holding alongside stable institutional participation may influence investor sentiment, as a strong promoter holding is often perceived as a sign of confidence in the company’s future prospects. Overall, while there is a solid retail base, the trend in promoter ownership could be a potential red flag for some investors.
Outlook, Risks, and Final Insight
Aarti Pharmalabs is positioned within a competitive pharmaceutical landscape, with strengths including solid profitability metrics, a healthy balance sheet, and a diverse shareholder base. However, risks such as declining sales trends, a high cash conversion cycle, and decreasing promoter ownership could pose challenges to its future performance. The company must focus on improving its operational efficiency and managing working capital effectively to navigate these challenges. Additionally, maintaining investor confidence will be crucial, especially as the market reacts to changes in promoter stakes and overall company performance. The outlook hinges on the company’s ability to innovate and adapt to market demands while ensuring sustainable growth. Should Aarti Pharmalabs successfully address these risks, it could potentially enhance its market positioning and profitability, but failure to do so could result in further erosion of investor confidence and financial performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 100 | 210/84.3 | 28.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,407 Cr. | 404 | 479/192 | 91.3 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.0 Cr. | 39.6 | 41.0/17.0 | 138 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,548.27 Cr | 1,144.26 | 53.57 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 531 | 472 | 485 | 458 | 440 | 449 | 506 | 555 | 458 | 538 | 564 | 386 | 418 |
| Expenses | 441 | 385 | 405 | 373 | 352 | 353 | 388 | 459 | 364 | 409 | 418 | 293 | 344 |
| Operating Profit | 90 | 86 | 80 | 85 | 88 | 96 | 118 | 96 | 94 | 129 | 146 | 93 | 74 |
| OPM % | 17% | 18% | 16% | 19% | 20% | 21% | 23% | 17% | 20% | 24% | 26% | 24% | 18% |
| Other Income | 1 | 0 | 1 | 0 | 1 | 1 | 2 | 2 | 4 | 5 | -2 | 2 | 0 |
| Interest | 6 | 5 | 6 | 4 | 4 | 4 | 5 | 5 | 6 | 10 | 7 | 7 | 11 |
| Depreciation | 17 | 16 | 16 | 17 | 18 | 19 | 19 | 20 | 21 | 23 | 23 | 23 | 25 |
| Profit before tax | 69 | 65 | 59 | 64 | 67 | 74 | 96 | 74 | 72 | 101 | 115 | 65 | 39 |
| Tax % | 26% | 27% | 27% | 26% | 23% | 29% | 32% | 25% | 24% | 26% | 23% | 24% | 28% |
| Net Profit | 51 | 48 | 43 | 47 | 52 | 53 | 65 | 55 | 55 | 74 | 88 | 50 | 28 |
| EPS in Rs | 5.26 | 4.73 | 5.20 | 5.72 | 5.82 | 7.20 | 6.12 | 6.03 | 8.16 | 9.75 | 5.46 | 3.08 |
Last Updated: December 28, 2025, 10:35 am
Below is a detailed analysis of the quarterly data for Aarti Pharmalabs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 418.00 Cr.. The value appears strong and on an upward trend. It has increased from 386.00 Cr. (Jun 2025) to 418.00 Cr., marking an increase of 32.00 Cr..
- For Expenses, as of Sep 2025, the value is 344.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 293.00 Cr. (Jun 2025) to 344.00 Cr., marking an increase of 51.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 74.00 Cr.. The value appears to be declining and may need further review. It has decreased from 93.00 Cr. (Jun 2025) to 74.00 Cr., marking a decrease of 19.00 Cr..
- For OPM %, as of Sep 2025, the value is 18.00%. The value appears to be declining and may need further review. It has decreased from 24.00% (Jun 2025) to 18.00%, marking a decrease of 6.00%.
- For Other Income, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Jun 2025) to 0.00 Cr., marking a decrease of 2.00 Cr..
- For Interest, as of Sep 2025, the value is 11.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7.00 Cr. (Jun 2025) to 11.00 Cr., marking an increase of 4.00 Cr..
- For Depreciation, as of Sep 2025, the value is 25.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 23.00 Cr. (Jun 2025) to 25.00 Cr., marking an increase of 2.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 39.00 Cr.. The value appears to be declining and may need further review. It has decreased from 65.00 Cr. (Jun 2025) to 39.00 Cr., marking a decrease of 26.00 Cr..
- For Tax %, as of Sep 2025, the value is 28.00%. The value appears to be increasing, which may not be favorable. It has increased from 24.00% (Jun 2025) to 28.00%, marking an increase of 4.00%.
- For Net Profit, as of Sep 2025, the value is 28.00 Cr.. The value appears to be declining and may need further review. It has decreased from 50.00 Cr. (Jun 2025) to 28.00 Cr., marking a decrease of 22.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 3.08. The value appears to be declining and may need further review. It has decreased from 5.46 (Jun 2025) to 3.08, marking a decrease of 2.38.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:21 am
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|
| Sales | 0 | 1,200 | 1,945 | 1,853 | 2,115 | 1,906 |
| Expenses | 0 | 993 | 1,603 | 1,467 | 1,651 | 1,464 |
| Operating Profit | 0 | 207 | 342 | 386 | 464 | 442 |
| OPM % | 17% | 18% | 21% | 22% | 23% | |
| Other Income | 0 | 3 | 2 | 5 | 10 | 5 |
| Interest | 0 | 12 | 21 | 17 | 27 | 34 |
| Depreciation | 0 | 42 | 63 | 73 | 87 | 93 |
| Profit before tax | 0 | 155 | 261 | 300 | 361 | 319 |
| Tax % | 21% | 26% | 28% | 24% | ||
| Net Profit | 0 | 122 | 193 | 217 | 272 | 240 |
| EPS in Rs | 21.35 | 23.93 | 30.05 | 26.45 | ||
| Dividend Payout % | 0% | 9% | 13% | 17% |
YoY Net Profit Growth
| Year | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|
| YoY Net Profit Growth (%) | 58.20% | 12.44% | 25.35% |
| Change in YoY Net Profit Growth (%) | 0.00% | -45.76% | 12.91% |
Aarti Pharmalabs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 3 years from 2022-2023 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 21% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 31% |
| TTM: | 18% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 28% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 14% |
| Last Year: | 15% |
Last Updated: September 5, 2025, 2:01 pm
Balance Sheet
Last Updated: December 4, 2025, 2:16 am
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|
| Equity Capital | 0.25 | 0.25 | 45 | 45 | 45 | 45 |
| Reserves | -0 | 1,386 | 1,513 | 1,712 | 1,945 | 2,001 |
| Borrowings | 0 | 341 | 215 | 285 | 413 | 659 |
| Other Liabilities | 0 | 312 | 470 | 540 | 503 | 561 |
| Total Liabilities | 0 | 2,040 | 2,244 | 2,582 | 2,906 | 3,266 |
| Fixed Assets | 0 | 782 | 926 | 1,033 | 1,137 | 1,515 |
| CWIP | 0 | 187 | 102 | 137 | 374 | 160 |
| Investments | 0 | 32 | 87 | 107 | 77 | 187 |
| Other Assets | 0 | 1,038 | 1,130 | 1,305 | 1,319 | 1,403 |
| Total Assets | 0 | 2,040 | 2,244 | 2,582 | 2,906 | 3,266 |
Below is a detailed analysis of the balance sheet data for Aarti Pharmalabs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 45.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 45.00 Cr..
- For Reserves, as of Sep 2025, the value is 2,001.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,945.00 Cr. (Mar 2025) to 2,001.00 Cr., marking an increase of 56.00 Cr..
- For Borrowings, as of Sep 2025, the value is 659.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 413.00 Cr. (Mar 2025) to 659.00 Cr., marking an increase of 246.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 561.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 503.00 Cr. (Mar 2025) to 561.00 Cr., marking an increase of 58.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 3,266.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,906.00 Cr. (Mar 2025) to 3,266.00 Cr., marking an increase of 360.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,515.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,137.00 Cr. (Mar 2025) to 1,515.00 Cr., marking an increase of 378.00 Cr..
- For CWIP, as of Sep 2025, the value is 160.00 Cr.. The value appears to be declining and may need further review. It has decreased from 374.00 Cr. (Mar 2025) to 160.00 Cr., marking a decrease of 214.00 Cr..
- For Investments, as of Sep 2025, the value is 187.00 Cr.. The value appears strong and on an upward trend. It has increased from 77.00 Cr. (Mar 2025) to 187.00 Cr., marking an increase of 110.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,403.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,319.00 Cr. (Mar 2025) to 1,403.00 Cr., marking an increase of 84.00 Cr..
- For Total Assets, as of Sep 2025, the value is 3,266.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,906.00 Cr. (Mar 2025) to 3,266.00 Cr., marking an increase of 360.00 Cr..
Notably, the Reserves (2,001.00 Cr.) exceed the Borrowings (659.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Free Cash Flow | 0.00 | -134.00 | 127.00 | 101.00 | 51.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Debtor Days | 115 | 84 | 102 | 99 | |
| Inventory Days | 272 | 188 | 230 | 190 | |
| Days Payable | 123 | 106 | 135 | 90 | |
| Cash Conversion Cycle | 264 | 166 | 197 | 200 | |
| Working Capital Days | 111 | 94 | 110 | 105 | |
| ROCE % | 19% | 16% | 17% | 17% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Multi Cap Fund | 428,834 | 0.15 | 30.05 | 428,834 | 2025-04-22 15:56:51 | 0% |
| ICICI Prudential Childrens Fund | 100,000 | 0.49 | 7.01 | N/A | N/A | N/A |
| ICICI Prudential Exports and Services Fund | 100,000 | 0.49 | 7.01 | N/A | N/A | N/A |
| Taurus Flexi Cap Fund | 72,058 | 1.38 | 5.05 | 59,058 | 2025-12-15 01:09:15 | 22.01% |
| HDFC Large and Mid Cap Fund | 67,500 | 0.02 | 4.73 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 10.00 |
| Basic EPS (Rs.) | 30.06 | 23.93 | 21.35 | 13.49 |
| Diluted EPS (Rs.) | 30.04 | 23.93 | 21.35 | 13.49 |
| Cash EPS (Rs.) | 39.64 | 32.01 | 28.25 | 36.08 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 219.55 | 193.88 | 171.97 | 304.30 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 219.55 | 193.88 | 171.97 | 304.30 |
| Revenue From Operations / Share (Rs.) | 233.36 | 204.42 | 214.64 | 263.36 |
| PBDIT / Share (Rs.) | 52.35 | 43.14 | 38.00 | 45.97 |
| PBIT / Share (Rs.) | 42.76 | 35.06 | 31.10 | 36.73 |
| PBT / Share (Rs.) | 39.80 | 33.16 | 28.77 | 34.10 |
| Net Profit / Share (Rs.) | 30.06 | 23.93 | 21.35 | 26.83 |
| NP After MI And SOA / Share (Rs.) | 30.06 | 23.93 | 21.35 | 26.83 |
| PBDIT Margin (%) | 22.43 | 21.10 | 17.70 | 17.45 |
| PBIT Margin (%) | 18.32 | 17.14 | 14.48 | 13.94 |
| PBT Margin (%) | 17.05 | 16.21 | 13.40 | 12.94 |
| Net Profit Margin (%) | 12.87 | 11.70 | 9.94 | 10.18 |
| NP After MI And SOA Margin (%) | 12.87 | 11.70 | 9.94 | 10.18 |
| Return on Networth / Equity (%) | 13.68 | 12.34 | 12.41 | 8.81 |
| Return on Capital Employeed (%) | 17.23 | 16.83 | 17.19 | 11.46 |
| Return On Assets (%) | 9.37 | 8.40 | 8.67 | 5.99 |
| Long Term Debt / Equity (X) | 0.05 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.19 | 0.15 | 0.13 | 0.24 |
| Asset Turnover Ratio (%) | 0.77 | 0.76 | 0.75 | 0.00 |
| Current Ratio (X) | 2.01 | 1.94 | 1.95 | 1.77 |
| Quick Ratio (X) | 1.12 | 1.01 | 0.93 | 0.95 |
| Inventory Turnover Ratio (X) | 3.44 | 1.38 | 1.78 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 11.64 | 8.35 | 10.04 | 2.02 |
| Dividend Payout Ratio (CP) (%) | 8.82 | 6.24 | 7.59 | 1.50 |
| Earning Retention Ratio (%) | 88.36 | 91.65 | 89.96 | 97.98 |
| Cash Earning Retention Ratio (%) | 91.18 | 93.76 | 92.41 | 98.50 |
| Interest Coverage Ratio (X) | 17.64 | 22.71 | 16.36 | 17.52 |
| Interest Coverage Ratio (Post Tax) (X) | 11.13 | 13.60 | 10.19 | 11.22 |
| Enterprise Value (Cr.) | 7172.16 | 4182.27 | 2678.01 | 0.00 |
| EV / Net Operating Revenue (X) | 3.39 | 2.26 | 1.38 | 0.00 |
| EV / EBITDA (X) | 15.12 | 10.70 | 7.78 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 3.21 | 2.13 | 1.28 | 0.00 |
| Retention Ratios (%) | 88.35 | 91.64 | 89.95 | 97.97 |
| Price / BV (X) | 3.41 | 2.24 | 1.60 | 0.00 |
| Price / Net Operating Revenue (X) | 3.21 | 2.13 | 1.28 | 0.00 |
| EarningsYield | 0.04 | 0.05 | 0.07 | 0.00 |
After reviewing the key financial ratios for Aarti Pharmalabs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 30.06. This value is within the healthy range. It has increased from 23.93 (Mar 24) to 30.06, marking an increase of 6.13.
- For Diluted EPS (Rs.), as of Mar 25, the value is 30.04. This value is within the healthy range. It has increased from 23.93 (Mar 24) to 30.04, marking an increase of 6.11.
- For Cash EPS (Rs.), as of Mar 25, the value is 39.64. This value is within the healthy range. It has increased from 32.01 (Mar 24) to 39.64, marking an increase of 7.63.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 219.55. It has increased from 193.88 (Mar 24) to 219.55, marking an increase of 25.67.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 219.55. It has increased from 193.88 (Mar 24) to 219.55, marking an increase of 25.67.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 233.36. It has increased from 204.42 (Mar 24) to 233.36, marking an increase of 28.94.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 52.35. This value is within the healthy range. It has increased from 43.14 (Mar 24) to 52.35, marking an increase of 9.21.
- For PBIT / Share (Rs.), as of Mar 25, the value is 42.76. This value is within the healthy range. It has increased from 35.06 (Mar 24) to 42.76, marking an increase of 7.70.
- For PBT / Share (Rs.), as of Mar 25, the value is 39.80. This value is within the healthy range. It has increased from 33.16 (Mar 24) to 39.80, marking an increase of 6.64.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 30.06. This value is within the healthy range. It has increased from 23.93 (Mar 24) to 30.06, marking an increase of 6.13.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 30.06. This value is within the healthy range. It has increased from 23.93 (Mar 24) to 30.06, marking an increase of 6.13.
- For PBDIT Margin (%), as of Mar 25, the value is 22.43. This value is within the healthy range. It has increased from 21.10 (Mar 24) to 22.43, marking an increase of 1.33.
- For PBIT Margin (%), as of Mar 25, the value is 18.32. This value is within the healthy range. It has increased from 17.14 (Mar 24) to 18.32, marking an increase of 1.18.
- For PBT Margin (%), as of Mar 25, the value is 17.05. This value is within the healthy range. It has increased from 16.21 (Mar 24) to 17.05, marking an increase of 0.84.
- For Net Profit Margin (%), as of Mar 25, the value is 12.87. This value exceeds the healthy maximum of 10. It has increased from 11.70 (Mar 24) to 12.87, marking an increase of 1.17.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 12.87. This value is within the healthy range. It has increased from 11.70 (Mar 24) to 12.87, marking an increase of 1.17.
- For Return on Networth / Equity (%), as of Mar 25, the value is 13.68. This value is below the healthy minimum of 15. It has increased from 12.34 (Mar 24) to 13.68, marking an increase of 1.34.
- For Return on Capital Employeed (%), as of Mar 25, the value is 17.23. This value is within the healthy range. It has increased from 16.83 (Mar 24) to 17.23, marking an increase of 0.40.
- For Return On Assets (%), as of Mar 25, the value is 9.37. This value is within the healthy range. It has increased from 8.40 (Mar 24) to 9.37, marking an increase of 0.97.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.05, marking an increase of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.19. This value is within the healthy range. It has increased from 0.15 (Mar 24) to 0.19, marking an increase of 0.04.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.77. It has increased from 0.76 (Mar 24) to 0.77, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 2.01. This value is within the healthy range. It has increased from 1.94 (Mar 24) to 2.01, marking an increase of 0.07.
- For Quick Ratio (X), as of Mar 25, the value is 1.12. This value is within the healthy range. It has increased from 1.01 (Mar 24) to 1.12, marking an increase of 0.11.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.44. This value is below the healthy minimum of 4. It has increased from 1.38 (Mar 24) to 3.44, marking an increase of 2.06.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 11.64. This value is below the healthy minimum of 20. It has increased from 8.35 (Mar 24) to 11.64, marking an increase of 3.29.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.82. This value is below the healthy minimum of 20. It has increased from 6.24 (Mar 24) to 8.82, marking an increase of 2.58.
- For Earning Retention Ratio (%), as of Mar 25, the value is 88.36. This value exceeds the healthy maximum of 70. It has decreased from 91.65 (Mar 24) to 88.36, marking a decrease of 3.29.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.18. This value exceeds the healthy maximum of 70. It has decreased from 93.76 (Mar 24) to 91.18, marking a decrease of 2.58.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 17.64. This value is within the healthy range. It has decreased from 22.71 (Mar 24) to 17.64, marking a decrease of 5.07.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 11.13. This value is within the healthy range. It has decreased from 13.60 (Mar 24) to 11.13, marking a decrease of 2.47.
- For Enterprise Value (Cr.), as of Mar 25, the value is 7,172.16. It has increased from 4,182.27 (Mar 24) to 7,172.16, marking an increase of 2,989.89.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.39. This value exceeds the healthy maximum of 3. It has increased from 2.26 (Mar 24) to 3.39, marking an increase of 1.13.
- For EV / EBITDA (X), as of Mar 25, the value is 15.12. This value exceeds the healthy maximum of 15. It has increased from 10.70 (Mar 24) to 15.12, marking an increase of 4.42.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has increased from 2.13 (Mar 24) to 3.21, marking an increase of 1.08.
- For Retention Ratios (%), as of Mar 25, the value is 88.35. This value exceeds the healthy maximum of 70. It has decreased from 91.64 (Mar 24) to 88.35, marking a decrease of 3.29.
- For Price / BV (X), as of Mar 25, the value is 3.41. This value exceeds the healthy maximum of 3. It has increased from 2.24 (Mar 24) to 3.41, marking an increase of 1.17.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has increased from 2.13 (Mar 24) to 3.21, marking an increase of 1.08.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to 0.04, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aarti Pharmalabs Ltd:
- Net Profit Margin: 12.87%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 17.23% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 13.68% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 11.13
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.12
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 27.6 (Industry average Stock P/E: 53.57)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.19
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.87%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot No 22/C/1 & 22/C/2, Vapi Gujarat 396195 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Chandrakant Vallabhaji Gogri | Chairman Emeritus |
| Mr. Rashesh C Gogri | Chairman & Non-Exe.Director |
| Mrs. Hetal Gogri Gala | Vice Chairperson & M.D |
| Mr. Narendra J Salvi | Managing Director |
| Mr. Rajendra V Gogri | Non Executive Director |
| Mr. Parimal H Desai | Non Executive Director |
| Ms. Nehal Garewal | Non Executive Director |
| Mr. Bhavesh R Vora | Independent Director |
| Mrs. Jeenal K Savla | Independent Director |
| Mrs. Rupal A Vora | Independent Director |
| Mr. Vilas Gajanan Gaikar | Independent Director |
| Dr. Vinay G Nayak | Independent Director |
| Mr. Pradeep H Thakur | Independent Director |
FAQ
What is the intrinsic value of Aarti Pharmalabs Ltd?
Aarti Pharmalabs Ltd's intrinsic value (as of 09 January 2026) is ₹728.48 which is 0.21% lower the current market price of ₹730.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹6,620 Cr. market cap, FY2025-2026 high/low of ₹972/557, reserves of ₹2,001 Cr, and liabilities of ₹3,266 Cr.
What is the Market Cap of Aarti Pharmalabs Ltd?
The Market Cap of Aarti Pharmalabs Ltd is 6,620 Cr..
What is the current Stock Price of Aarti Pharmalabs Ltd as on 09 January 2026?
The current stock price of Aarti Pharmalabs Ltd as on 09 January 2026 is ₹730.
What is the High / Low of Aarti Pharmalabs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Aarti Pharmalabs Ltd stocks is ₹972/557.
What is the Stock P/E of Aarti Pharmalabs Ltd?
The Stock P/E of Aarti Pharmalabs Ltd is 27.6.
What is the Book Value of Aarti Pharmalabs Ltd?
The Book Value of Aarti Pharmalabs Ltd is 226.
What is the Dividend Yield of Aarti Pharmalabs Ltd?
The Dividend Yield of Aarti Pharmalabs Ltd is 0.68 %.
What is the ROCE of Aarti Pharmalabs Ltd?
The ROCE of Aarti Pharmalabs Ltd is 17.4 %.
What is the ROE of Aarti Pharmalabs Ltd?
The ROE of Aarti Pharmalabs Ltd is 14.5 %.
What is the Face Value of Aarti Pharmalabs Ltd?
The Face Value of Aarti Pharmalabs Ltd is 5.00.